A PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS

干细胞治疗艾滋病的安全性和可行性试点研究

• 批准号: 7716664
• 负责人: AMRITA KRISHNAN
• 金额: $ 0.11万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716664
• 关键词: AIDS-Related Lymphoma; Anti-HIV Therapy; Autologous; Autologous Stem Cell Transplantation; Autologous Transplantation; Behavior Therapy; Blood Component Removal; CCR5 gene; CD34 gene; Carmustine; Catalytic RNA; Cells; Cities; Collection; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Cytokine Receptors; Elements; Etoposide; Exons; Funding; Gene Transfer; Grant; HIV; HIV-1; Hematopoietic stem cells; Hour; Infection; Institution; Lentivirus Vector; Patients; Pilot Projects; RNA; RNA Interference; Research; Research Institute; Research Personnel; Resources; Safety; Source; Standards of Weights and Measures; Subfamily lentivirinae; System; Time; Transfer RNA; United States National Institutes of Health; VP 16; base; cellular transduction; small hairpin RNA; stem cell therapy; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pilot study to determine the safety and feasibility of gene transfer of RNA-based anti-HIV therapy expressed in lentivirus-transduced hematopoietic progenitor cells (HPC) in patients undergoing autologous stem cell transplantation (HCT) for intermediate and high grade AIDS lymphoma. The lentivirus vector encodes 3 forms of anti-HIV RNA: RNAi in the form of a short hairpin RNA (shRNA) targeted to an exon in HIV-1 tat/rev (shI), a decoy for the HIV TAT-reactive element (TAR) and a ribozyme that targets the host cell CCR5 cytokine receptor (CCR5RZ) . The vector, used to transduce autologous CD34-selected HPC, is called rHIV7-shI-TAR-CCR5RZ and will be produced by the Beckman Research Institute at City of Hope. Following standard mobilization of HPC and collection by apheresis (HPC-A), a portion of the cells will be cryopreserved but otherwise unmanipulated for later use as treatment and a portion will be enriched for CD34+ cells using a Miltenyi CliniMacs system, cryopreserved and later genetically modified by infection with rHIV7-shI-TAR-CCR5RZ. The subjects will undergo conditioning therapy using carmustine (BCNU), etoposide (VP16) and cyclophosphamide, and at the time of autologous transplantation (HCT), the rHIV7-shI-TAR-CCR5RZ transduced cells will be infused and then 24 hours later, the untransduced autologous HPC-A will be infused.

这个子项目是众多研究子项目之一